STUDY OF INFECTIOUS COMPLICATIONS IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB

被引：0
|
作者：
Diaz, Galvez Francisco J. [1 ]
Barrigon Fernando, Escalante [2 ]
Vals Julio, Davila [3 ]
Saavedra Veronica, Campuzano [1 ]
Gomez Jorge, Labrador [1 ]
Garcia Abelardo, Barez [3 ]
Maria Del Carmen, Hermoso Martinez [3 ]
Nuno Rodolfo, Alvarez [1 ]
机构：
[1] Hosp Univ Burgos, Burgos, Spain
[2] Complejo Asistencial Univ Leon, Leon, Spain
[3] Complejo Asistencial Avila, Avila, Spain
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-015
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [31] Use of a Cord Blood Panel for Daratumumab Treated Multiple Myeloma Patients in a Clinical Setting
    Barry, Maria
    Armstrong, Braden
    TRANSFUSION, 2017, 57 : 161A - 162A
  • [32] Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens
    De Novellis, Danilo
    Fontana, Raffaele
    Serio, Bianca
    Vaccaro, Emilia
    Guariglia, Roberto
    Morini, Denise
    Rizzo, Michela
    Giudice, Valentina
    Selleri, Carmine
    CANCER MEDICINE, 2024, 13 (14):
  • [33] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [34] Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
    McCudden, Christopher
    Axel, Amy E.
    Slaets, Dominique
    Dejoie, Thomas
    Clemens, Pamela L.
    Frans, Sandy
    Bald, Jaime
    Plesner, Torben
    Jacobs, Joannes F. M.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Schecter, Jordan M.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (06) : 1095 - 1104
  • [35] Renal, hematologic and infectious complications in multiple myeloma
    Bladé, J
    Rosiñol, L
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) : 635 - 652
  • [36] Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab
    Chari, Ajai
    Satta, Toshihisa
    Tayal, Amit
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Lau, Kenneth
    Morgan, Gillian
    Catamero, Donna
    Escalon, Juliet
    Florendo, Erika
    Verina, Daniel
    Doshi, Parul
    Feng, Huaibao
    Uhlar, Clarissa
    Khan, Imran
    Ahmadi, Tahamtan
    Voorhees, Peter M.
    Mateos, Maria-Victoria
    Arinsburg, Suzanne
    BLOOD, 2015, 126 (23)
  • [37] Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
    Bahlis, Nizar J.
    Zonder, Jeffrey A.
    Wroblewski, Susan
    Qi, Ming
    Renaud, Thomas
    Jackson, Carolyn Chang
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
  • [39] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    BLOOD, 2022, 140 : 13202 - 13203
  • [40] Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?
    de la Rubia, Javier
    Cejalvo, Maria J.
    Ribas, Paz
    LEUKEMIA & LYMPHOMA, 2016, 57 (02) : 258 - 268
12345